

CLAIM AMENDMENTS

1. (Original) An antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass.
2. (Original) The antigen according to claim 1, wherein the tumor mass is a solid tumor formed by subcutaneous transplantation of a cultured cancer cell.
3. (Currently Amended) The antigen according to claim 1 ~~or 2~~, wherein the existing amount of the antigen of the solid tumor is increased in comparison with that of a cultured cell of the solid tumor.
4. (Currently Amended) The antigen according to ~~any one of claims 1 to 3~~ claim 1, wherein the existing amount of the antigen of the solid tumor on the cell surface is increased in comparison with that of a cultured cell of the solid tumor.
5. (Currently Amended) The antigen according to ~~any one of claims 1 to 4~~ claim 1, which is a cytoskeleton protein or a mutant thereof.
6. (Currently Amended) The antigen according to ~~any one of claims 1 to 5~~ claim 1, which is myosin or a mutant thereof.
7. (Currently Amended) The antigen according to ~~any one of claims 1 to 6~~ claim 1, which is a non-muscular myosin heavy chain type A or a mutant thereof.
8. (Currently Amended) The antigen according to ~~any one of claims 1 to 7~~ claim 1, which is a part of a non-muscular myosin heavy chain type A or a mutant thereof.
9. (Currently Amended) The antigen according to ~~any one of claims 1 to 8~~ claim 1, which is a sequence of a C-terminal domain of the protein sequence of a non-muscular myosin heavy chain type A or a mutant thereof.
10. (Original) The antigen according to claim 9, wherein the sequence of a C-terminal domain of the protein sequence is a sequence of the residue at position 600 to the residue at position 1,960 from the N-terminal of SEQ ID NO:17 in the Sequence Listing.

11. (Original) The antigen according to claim 9, wherein the sequence of a C-terminal domain of the protein sequence is any one of SEQ ID NOs:20, 21 and 22.

12. (Currently Amended) A ligand which recognizes the antigen according to ~~any one of claims 1 to 11~~ claim 1.

13. (Original) The ligand according to claim 12, which is an antibody.

14. (Currently Amended) The ligand according to claim 12 ~~or 13~~, which is a monoclonal antibody.

15. (Currently Amended) The ligand according to ~~any one of claims 12 to 14~~ claim 12, wherein the monoclonal antibody is a human monoclonal antibody.

16. (Currently Amended) The ligand according to ~~any one of claims 12 to 15~~ claim 12, which is a cancer reactive monoclonal antibody.

17. (Original) The ligand according to claim 16, wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.

18. (Currently Amended) The ligand according to ~~any one of claims 12 to 17~~ claim 12, wherein a heavy chain hypervariable region comprises the amino acid sequences of SEQ ID NOs:1, 2 and 3 in the Sequence Listing, and a light chain hypervariable region comprises the amino acid sequences of SEQ ID NOs:4, 5 and 6 in the Sequence Listing.

19. (Currently Amended) The ligand according to ~~any one of claims 12 to 18~~ claim 12, which comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 in the Sequence Listing and a light chain variable region containing the amino acid sequence of SEQ ID NO:8 in the Sequence Listing.

20. (Currently Amended) A pharmaceutical composition, which comprises the ligand according to ~~any one of claims 12 to 19~~ claim 12 and a pharmaceutically acceptable carrier.

21. (Original) The pharmaceutical composition according to claim 20, which is a targeting therapy agent.

22. (Currently Amended) The pharmaceutical composition according to claim 20 ~~or 21~~, which targets at a cancer tissue or a cancer cell.

23. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 20 to 22~~ claim 20, which comprises an antitumor agent, an antitumor protein, an enzyme, a gene or an isotope for treatment.

24. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 20 to 23~~ claim 20, which is an antitumor agent.

25. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 20 to 24~~ claim 20, wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.

26. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 20 to 25~~ claim 20, which comprises liposome.

27. (Currently Amended) A ~~labeling agent composition~~, which comprises the ligand according to ~~any one of claims 12 to 19~~ claim 12 and a labeling agent.

28. (Currently Amended) The ~~labeling agent composition~~ according to claim 27, which specifically labels a cancer tissue or a cancer cell.

29. (Currently Amended) The ~~labeling agent composition~~ according to claim 27 ~~or 28~~, wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.

30. (Currently Amended) The ~~labeling agent composition~~ according to ~~any one of claims 27 to 29, which comprises~~ claim 27, wherein the labeling agent is a fluorescent, an enzyme, an isotope or an MRI contrast medium.

31. (Currently Amended) A method for treating a cancer disease of a cancer disease patient ~~which expresses the antigen according to any one of claims 1 to 11~~, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to any one of claims 20 to 26 claim 20,

wherein the cancer disease patient expresses an antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass.

32. (Currently Amended) A method for treating a cancer disease of a cancer disease patient ~~having a cell which can be labeled by the labeling agent according to any one of claims 27 to 30~~, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to any one of claims 20 to 26 claim 20,
wherein the cancer disease patient has a cell which can be labeled by a composition comprising a ligand which recognizes an antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass, and a labeling agent.

33. (Currently Amended) The ligand according to ~~any one of claims 12 to 19 claim 12~~, wherein the binding activity of the ligand which recognizes the an antigen according to any one of claims 1 to 11 having a part which is exposed on the surface of a cell at the formation of a tumor mass to the antigen is from 0.5×10^6 units/mg to 2.0×10^6 units/mg.

34. (Currently Amended) The ligand according to ~~any one of claims 12 to 19 claim 12~~, wherein the binding activity is from 0.7×10^6 units/mg to 1.5×10^6 units/mg, from 0.7×10^6 units/mg to 1.3×10^6 units/mg, or from 0.8×10^6 units/mg to 1.2×10^6 units/mg.

35. (Currently Amended) The ligand according to ~~any one of claims 12 to 19 claim 12~~, wherein the binding activity is from 0.8×10^6 units/mg to 1.2×10^6 units/mg.